Dermata Therapeutics
DRMA
7 hedge funds and large institutions have $129K invested in Dermata Therapeutics in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
107% more capital invested
Capital invested by funds: $62.4K → $129K (+$66.5K)
0.03% more ownership
Funds ownership: 2.62% → 2.65% (+0.03%)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$81.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$57.8K |
| 3 |
WF
Welch & Forbes
Boston,
Massachusetts
|
+$33.7K |
| 4 |
MA
MCF Advisors
Covington,
Kentucky
|
+$2.92K |
| 5 |
Citigroup
New York
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$39.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$8.02K |
| 3 |
Barclays
London,
United Kingdom
|
-$5.57K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.16K |
| 5 |
JP Morgan Chase
New York
|
-$1.61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $58.5K | +$81.3K | +48,334 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $43.1K | +$57.8K | +34,371 | +2,779% |
|
|
WF
3
Welch & Forbes
Boston,
Massachusetts
| $24.2K | +$33.7K | +20,000 | New |
|
|
MA
4
MCF Advisors
Covington,
Kentucky
| $2.1K | +$2.92K | +1,732 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $866 | -$2.16K | -1,283 | -64% |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| $122 | – | – | – |
|
|
7
Citigroup
New York
| $1 | +$2 | +1 | New |
|
|
CS
8
Clear Street
New York
| – | -$39.4K | -17,000 | Closed |
|
|
9
Bank of America
Charlotte,
North Carolina
| – | -$8.02K | -3,457 | Closed |
|
|
10
Barclays
London,
United Kingdom
| – | -$5.57K | -2,402 | Closed |
|
|
11
JP Morgan Chase
New York
| – | -$1.61K | -696 | Closed |
|
DRMA Hedge Fund Activity: Q1 2026 in Review
7 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q1 2026, worth a combined $129K — up 107% from $62.4K a quarter earlier.
Fund positioning in DRMA was balanced in Q1 2026: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $81.3K. The largest seller was Clear Street, exiting entirely with an estimated $39.4K sold.
- 7 institutional investors held Dermata Therapeutics (DRMA) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $129K of Dermata Therapeutics stock for Q1 2026, up 107% quarter-over-quarter.
- 4 funds opened new Dermata Therapeutics positions in Q1 2026 and 4 closed out, a net change of 0 holders.
- The largest Dermata Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $81.3K added.
- The largest Dermata Therapeutics seller in Q1 2026 was Clear Street, an estimated $39.4K sold.
Based on aggregated 13F filings for Q1 2026.